Klemens Rappersberger

from Wikipedia, the free encyclopedia

Klemens Rappersberger (born March 29, 1958 in Linz ) is an Austrian specialist in dermatology and a university professor. He is professor of dermatology and dermato-oncology at the Sigmund Freud University in Vienna and head of the department for dermatology and venereology at the Vienna Rudolf Foundation . Rappersberger is known for his clinical-pathological studies of autoimmune diseases and skin tumors as well as ultrastructural, biochemical and molecular work in basic research.

Life

Rappersberger studied medicine at the University of Vienna from 1976 to 1982 and was trained as a specialist from 1982 to 1988 at the I. University Dermatology Clinic in Vienna with Klaus Wolff . In 1989 Rappersberger went to the University of Oslo (Norbert Roos) for electron microscopic research and then to Werner W. Franke at the Department of Membrane Biology and Biochemistry at the DKFZ in Heidelberg . In 1991 he qualified as a professor, became professor of dermatology at the Medical Faculty of the University of Vienna, and on January 1, 2000, he switched to the Rudolf Foundation . In 2016, Rappersberger was appointed full professor of dermatology at the Sigmund Freud Private University of the Medical Faculty.

Scientific contribution

  • Ultrastructural localization of autoantigens in desmosomes with the aid of immune electron microscopy on ultra-thin frozen sections and introduction of this technique into dermatological research
  • Investigation of the topical and systemic anti-inflammatory effectiveness of the calcineurin inhibitor “ Pimecrolimus ” and development of a new therapeutic agent: Elidel®
  • Proof of the therapeutic efficacy of inhaled IL-2 for lung metastases and of intravenous immunoglobulins for "livedoid vasculopathy"
  • Establishment of a melanoma research group: together with the University of California in San Francisco, Hellen Diller Comprehensive Cancer Center and Susana Ortiz-Urda with Martina Sanlorenzo, Christian Posch, Igor Vujic and Felix Weihsengruber

Honors and awards (selection)

Rappersberger was honored with various prizes for his scientific work. The Medical Faculty of the University of Vienna awarded him the “HOECHST Award” (1988), the Austrian Society for Dermatology and Venereology (ÖGDV) among others the “AESCA Award” (1988 and 1989), the HEBRA Award (1991) and the “Austrian Dermatologist Prize UNILEVER Award” (1994 and 2015). Further prizes are the Science Prize of the Government of Upper Austria (1996), the “ Kardinal Innitzer Prize for Promotion of Human and Veterinary Medicine ” (1997) and the Billroth Prize 2016.

Publications

Web links

Individual evidence

  1. ^ A b Sigmund Freud Private University, Klemens Rappersberger. Retrieved January 3, 2017 .
  2. ^ A b Vienna Hospital Association, Department of Dermatology and Venereology. Retrieved January 9, 2017 .
  3. ↑ K. Rappersberger, S. Gartner, P. Schenk, G. Stingl, V. Groh, E. Tschachler, DL Mann, K. Wolff, K. Konrad, M. Popovic: Langerhans' Cells Are an Actual Site of HIV- 1 replication. In: Intervirology. 29, 1988, pp. 185-194.
  4. ↑ K. Rappersberger, N. Roos, JR Stanley: Immunomorphologic and Biochemical Identification of the Pemphigus Foliaceous Autoantigen within Desmosomes. In: The Journal of Investigative Dermatology. 99, 1992, pp. 323-330.
  5. ↑ D. Foedinger, GJ Anhalt, B. Boecskoer, A. Elbe, K. Wolff, K. Rappersberger: Autoantibodies to Desmoplakin I and II in Patients with Erythema Multiforme. In: The Journal of Experimental Medicine. 181, 1995, pp. 169-179.
  6. ^ S. Ortiz-Urda, A. Elbe-Burger, J. Smolle, Y. Marquart, Y. Chudnovsky, TW Ridky, P. Bernstein, K. Wolff, K. Rappersberger: The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo. In: Journal of Immunology. 171, 2003, pp. 6244-6250.
  7. ↑ K. Rappersberger, JG Meingassner, R. Fialla, D. Födinger, B. Sterniczky, S. Rauch, E. Putz, A. Stütz, K. Wolff: Clearing of Psoriasis by a Novel Immunosuppressive Macrolide. In: The Journal of Investigative Dermatology. 106, 1996, pp. 701-710.
  8. ↑ Klemens Rappersberger, Michael Komar, Marie-Eve Ebelin, Graham Scott, Pascale Burtin, Gerard Greig, Jeanne Kehren et al .: Pimecrolimus Identifies a Common Genomic Anti-Inflammatory Profile, Is Clinically Highly Effective in Psoriasis and Is Well Tolerated. In: The Journal of Investigative Dermatology. 119, 2002, pp. 876-887.
  9. ↑ C. Posch, F. Weihsengruber, K. Bartsch, V. Feichtenschlager, M. Sanlorenzo, I. Vujic, B. Monshi, S. Ortiz-Urda, K. Rappersberger: Low-Dose Inhalation of Interleukin-2 Bio-Chemotherapy for the Treatment of Pulmonary Metastases in Melanoma Patients. In: British Journal of Cancer. 110, 2014, pp. 1427-1432.
  10. ↑ Babak Monshi, Christian Posch, Igor Vujic, Alma Sesti, Silke Sobotka, Klemens Rappersberger: Efficacy of Intravenous Immunoglobulins in Livedoid Vasculopathy: Long-Term Follow-up of 11 Patients. In: Journal of the American Academy of Dermatology. 71, 2014, pp. 738-744.
  11. Jump up ↑ C. Posch, H. Moslehi, M. Sanlorenzo, G. Green, I. Vujic, R. Panzer-Grümayer, K. Rappersberger, S. Ortiz-Urda: Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. In: Oncotarget. Jun 14, 2016. doi: 10.18632 / oncotarget.10001 . [Epub ahead of print]
  12. ↑ C. Posch, M. Sanlorenzo, I. Vujic, JA Oses-Prieto, BD Cholewa, ST Kim, J. Ma, K. Lai, M. Zekhtser, R. Esteve-Puig, G. Green, S. Chand, AL Burlingame, R. Panzer-Grümayer, K. Rappersberger, S. Ortiz-Urda: Phosphoproteomic Analyzes of NRAS (G12) and NRAS (Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS (Q61) Mutant Cells. In: The Journal of Investigate Dermatology. 136, 2016, pp. 2041-2048.
  13. ↑ C. Posch, I. Vujic, B. Monshi, M. Sanlorenzo, F. Weihsengruber, K. Rappersberger, S. Ortiz-Urda: Searching for the Chokehold of NRAS Mutant Melanoma. Review. In: J Invest Dermatol. 136, Jul 2016, pp. 1330-1336.
  14. Jump up ↑ B. Monshi, M. Vujic, D. Kivaranovic, A. Sesti, W. Oberaigner, I. Vujic, S. Ortiz-Urda, C. Posch, H. Feichtinger, M. Hackl, K. Rappersberger: The burden of malignant melanoma - lessons to be learned from Austria. In: Eur J Cancer. 56, 2016, pp. 45-53.
  15. ↑ I. Vujic, M. Sanlorenzo, R. Esteve-Puig, M. Vujic, A. Kwong, A. Tsumura, R. Murphy, A. Moy, C. Posch, B. Monshi, K. Rappersberger, S. Ortiz -Urda: Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. In: Oncotarget. 7, 2016, pp. 7297-7306.
  16. ^ C. Posch, BD Cholewa, I. Vujic, M. Sanlorenzo, J. Ma, ST Kim, S. Kleffel, T. Schatton, K. Rappersberger, R. Gutteridge, N. Ahmad, S. Ortiz-Urda: Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. In: The Journal of Investigative dermatology. 135, 2015, pp. 2475-2483.
  17. ↑ I. Vujic, M. Sanlorenzo, C. Posch, R. Esteve Puig, AJ Yen, A. Kwong, A. Tsumura, R. Murphy, K. Rappersberger, S. Ortiz-Urda: metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. In: Oncotarget. 6, 2015, pp. 969-978.
personal data
SURNAME Rappersberger, Klemens
BRIEF DESCRIPTION Austrian dermatologist
DATE OF BIRTH March 29, 1958
PLACE OF BIRTH Linz